| 来源类型 | Working Paper |
| 规范类型 | 报告 |
| DOI | 10.3386/w28349 |
| 来源ID | Working Paper 28349 |
| Private and Public Investments in Biomedical Research | |
| Maya M. Durvasula; Lisa Larrimore Ouellette; Heidi L. Williams | |
| 发表日期 | 2021-01-18 |
| 出版年 | 2021 |
| 语种 | 英语 |
| 摘要 | Recent policy attention has focused on proposals to reduce prices for drugs that have received public funding. From an implementation perspective, such policies rely on public disclosure of government support for research. In this paper, we highlight two conceptual problems with past attempts to measure these public disclosures, and construct a new data set which corrects for these problems. Our corrected measures suggest that under-reporting of public research support is less of an issue than previously thought. |
| 主题 | Health, Education, and Welfare ; Health ; Development and Growth ; Innovation and R& ; D |
| URL | https://www.nber.org/papers/w28349 |
| 来源智库 | National Bureau of Economic Research (United States) |
| 引用统计 | |
| 资源类型 | 智库出版物 |
| 条目标识符 | http://119.78.100.153/handle/2XGU8XDN/586020 |
| 推荐引用方式 GB/T 7714 | Maya M. Durvasula,Lisa Larrimore Ouellette,Heidi L. Williams. Private and Public Investments in Biomedical Research. 2021. |
| 条目包含的文件 | ||||||
| 文件名称/大小 | 资源类型 | 版本类型 | 开放类型 | 使用许可 | ||
| w28349.pdf（235KB） | 智库出版物 | 限制开放 | CC BY-NC-SA | 浏览 | ||
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
